Biomedical Engineering Reference
In-Depth Information
53. Guerin, M.,
, Overexpression of either c-myc or c-erbB-2/neu
proto-oncogenes in human breast carcinomas: correlation with poor
prognosis.
et al.
Oncogene Res
, 1988.
3
(1): 21-31.
54. Wolff, A.C.,
, American society of clinical oncology/college of
American pathologists guideline recommendations for human
epidermal growth factor receptor 2 testing in breast cancer.
et al.
J Clin
Oncol
, 2007.
25
(1): 118-145.
55. Baselga, J.,
, Recombinant humanized anti-HER2 antibody
(Herceptin) enhances the antitumor activity of paclitaxel and
doxorubicin against HER2/neu overexpressing human breast cancer
xenografts.
et al.
Cancer Res
, 1998.
58
(13): 2825-2831.
56. Press, M.F.,
, Sensitivity of HER-2/neu antibodies in archival tissue
samples: potential source of error in immunohistochemical studies of
oncogene expression.
et al.
Cancer Res
, 1994.
54
(10): 2771-2777.
57. Press, M.F.,
, Evaluation of HER-2/neu gene amplification and
overexpression: comparison of frequently used assay methods in a
molecularly characterized cohort of breast cancer specimens.
et al.
J Clin
Oncol
, 2002.
20
(14): 3095-3105.
58. Pauletti, G.,
, Detection and quantitation of HER-2/neu gene
amplification in human breast cancer archival material using
fluorescence
et al.
in situ
hybridization.
Oncogene
, 1996.
13
(1): 63-72.
59. Kallioniemi, O.P.,
, ERBB2 amplification in breast cancer analyzed
by fluorescence in situ hybridization.
et al.
Proc Natl Acad Sci U S A
, 1992.
(12): 5321-5325.
60. Naber, S.P.,
89
, Strategies for the analysis of oncogene overexpression.
Studies of the neu oncogene in breast carcinoma.
et al.
Am J Clin Pathol
,
(2): 125-136.
61. Press, M.F.,
1990.
94
, Diagnostic evaluation of HER-2 as a molecular target:
an assessment of accuracy and reproducibility of laboratory testing
in large, prospective, randomized clinical trials.
et al.
Clin Cancer Res
, 2005.
(18): 6598-6607.
62. Dietel, M.,
11
, Comparison of automated silver enhanced in situ
hybridisation (SISH) and fluorescence ISH (FISH) for the validation of
HER2 gene status in breast carcinoma according to the guidelines of
the American Society of Clinical Oncology and the College of American
Pathologists.
et al.
Virchows Arch
, 2007.
451
(1): 19-25.
63. Isola, J.,
, Interlaboratory comparison of HER-2 oncogene
amplification as detected by chromogenic and fluorescence
et al.
in situ
hybridization.
Clin Cancer Res
, 2004.
10
(14): 4793-4798.
